Policy & Regulation: Page 16
-
PharmaVoice Team/PharmaVoice
The C-Suite: Corporate Strategies
A New Path Ahead According to a recent Quintiles New Health report, a lack of capital and the increased reluctance of payers to reimburse for new medications are serious concerns among biopharma companies. Everyone is in agreement that the current level of healthcare spending is unsustainable, an...
By PharmaVoice Team • Nov. 13, 2012 -
PharmaVoice Team/PharmaVoice
Crystal Ball: What's Ahead
Getting Down to Business: What’s Ahead in 2013 Thought leaders from all sectors of the industry identify what they believe are the most important business objectives for the life-sciences industry and their companies for 2013 and beyond. They also provide their insights on the strategies/approac...
By PharmaVoice Team • Nov. 13, 2012 -
Explore the Trendline➔
Stock via Getty Images
TrendlineEmerging biotech
After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
On the Calendar
The Calendar Industry Events and Conferences, including SPECIAL DISCOUNTS Coming ATTRACTIONS Social Media, Mobile & Gaming for Pharma: How To Develop, Monitor, & Execute Digital Strategies To Engage Your Audiences, Strengthen Brand Awareness & Maximize Your Communication & Marketi...
By Taren Grom • Nov. 8, 2012 -
PharmaVoice Team/PharmaVoice
Compliance Issues? First, Don't Panic.
A hurricane is coming. You heard about it on the radio. Everyone in the family jumps to it. You rush to the grocery store and pile as many cans of Chef Boyardee as will fit in your cart. Your spouse nails boards across the windows. The kids run around the house collecting candles. But when the st...
By Greg Kain • Sept. 27, 2012 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Regulatory Affairs: Regulating the Globe
The growing pressure on pharma companies and regulators to ensure and enforce product potency and safety has resulted in a strong trend toward harmonization among regulatory bodies throughout the world. “Regulatory professionals can no longer operate with a local-only mentality; every product and...
By Carolyn Gretton • Sept. 27, 2012 -
PharmaVoice Team/PharmaVoice
China's Pharma Star Shines Bright
With a large patient population, government commitment to healthcare reform, a huge depth of scientific talent, and a powerful economy, China has been identified by many as the world’s most important emerging biopharma market. With a population of 1.3 billion people, China is both the world’s mos...
By Kim Ribbink • Sept. 27, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical Pool Dr. Lawrence Bloch Infinity Names Business Chief Lawrence Bloch, M.D., has joined Infinity Pharmaceuticals as executive VP, chief financial officer, and chief business officer. Dr. Bloch is responsible for the company’s corporate, financial, and business development strategies...
By Carolyn Gretton • Sept. 27, 2012 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Marketing: Marketing Without Wires
Throughout pharma history, marketers have always gone where the consumers are — and where they are today, in growing numbers, is on the mobile Web. An estimated 81% of physicians surveyed say they use a smartphone, while 75% specified using an Apple iPhone, iPad, or iPod, according to the Manhatt...
By PharmaVoice Team • Aug. 31, 2012 -
PharmaVoice Team/PharmaVoice
Facing the Challenges of Global Product Registration
Facing the Challenges of Global Product Registration Robin Robinson One could say keeping track of global product registrations and staying compliant with regional and international regulations is more difficult than herding cats — if that common phrase used to describe a situation where numerous...
By Robin Robinson • Aug. 30, 2012 -
PharmaVoice Team/PharmaVoice
The Era of Transparency
Now that the Supreme Court has upheld the constitutionality of the Affordable Care Act, pharmaceutical companies must continue to move forward to implement the provisions in the law. One such provision is the Physician Payment Sunshine Act, which requires manufacturers of pharmaceuticals and medi...
By Denise Myshko • Aug. 30, 2012 -
PharmaVoice Team/PharmaVoice
Hitting the Target with Behavioral Marketing
The concept of behavioral marketing is not new, but with the advent of technology and new marketing tools, the industry is able to connect with its consumers on a very individual level, creating the ability to impact behavior and health outcomes on an almost molecular scale. While data are crucia...
By PharmaVoice Team • Aug. 30, 2012 -
PharmaVoice Team/PharmaVoice
The Mentors
Kim Boericke Quintiles Tami Klerr-Naivar PRA Joe Martinez Optimer Pharmaceuticals Chuck McLeester Roska Healthcare Advertising Linda Rosenes Pfizer The Mentors Leading Through Excellence In addition to leading their organizations to reach new heights, these individuals take great pride in fosteri...
By PharmaVoice Team • July 28, 2012 -
PharmaVoice Team/PharmaVoice
Healthcare and the Political Landscape
Healthcare and the Political Landscape By Denise Myshko Healthcare reform remains front and center within the political arena. The major reforms contained in the Affordable Care Act are not scheduled to take effect until 2014, but the legislation faces legal and political challenges. In March, th...
By Denise Myshko • May 29, 2012 -
PharmaVoice Team/PharmaVoice
Innovation Through Drug Delivery
By Denise Myshko The increasing demand for effective delivery mechanisms of novel biopharmaceuticals is driving the growth of the drug delivery market. With formulation playing such a key role in the making of a successful product, the right delivery platform, partnership sourcing, and management...
By PharmaVoice Team • May 29, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
The New Business Model: Developing Payer-Friendly Drugs Through Partner Innovation John Chiminski, President and CEO of Catalent Pharma Solutions, discusses why a business model that uses technologies and new ways of working with providers to bring to market innovative products is critical to...
By John Chiminski • May 28, 2012 -
PharmaVoice Team/PharmaVoice
UK Revival: Rebuilding a Life Sciences World Leader
Kim Ribbink A long history as a world leader in innovation, talented scientists from well-respected universities, mature biotech clusters, and government incentives to attract innovative companies give the U.K. a clear edge, but this great scientific nation still has challenges with which to c...
By Kim Ribbink • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Safety and Pharmacovigilance: A Moving Target
Robin Robinson The industry has always been under extreme scrutiny by regulators and the public, but the current business environment creates even more pressure on the pharmaceutical industry to stay compliant. Regulations and procedures are not only tightening but continually developing and c...
By PharmaVoice Team • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Pharma 3.0 Next Steps
Robin Robinson Pharma Expands Disease Categories of 3.0 Efforts Between 2006 and 2009, 24% of Pharma 3.0 initiatives focused first on diabetes and metabolics. In 2010, oncology moved to the top with 15% of the year’s initiatives, and diabetes and metabolics tied for second with immunoscience/...
By PharmaVoice Team • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Alex AZAR Maria CROWE Dave RICKS Lilly Makes Management Changes Lilly has announced a number of key management appointments. Alex Azar has been promoted to president of Lilly USA, the company’s...
By Carolyn Gretton • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
New electronic and web-based applications, sites, and technologies By Carolyn Gretton ImpactRx Adds Tablet Detailing to Analytics Offerings Trend: Growing physician adoption of tablet computers is prompting pharma brand teams to design and execute messaging strategies that more effectively employ...
By Carolyn Gretton • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Building a Culture of Innovation
Pharmaceutical R&D is under pressure to counter rising costs, depleted pipelines, and impending patent expiries. The industry is facing not only a productivity crisis, but also a crisis in innovation. Industry analysts say many pharmaceutical and biopharma companies are turning their focus aw...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
C-Suite: Executive Insights
CEOs, presidents, and executive management team members from across the industry — pharmaceutical, biotechnology, and service companies — discuss the most crucial factors driving change in the industry, as well as their strategies for meeting the challenges of business in the coming years. Jed Be...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
What's Ahead for 2012
Our readers identified the top trends and game changers they expect to define the various industry sectors in the coming year. John Blakeley Executive VP and Chief Commercial Officer ERT, a clinical research service provider that assesses the safety of newly developed drugs by major pharmaceutica...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
On the Calendar
Industry Events and Conferences, including SPECIAL DISCOUNTS Coming ATTRACTIONS Attendees interested in maximizing their clinical trial performance by bridging the gap between identifying and implementing metrics, learning about best practices on processing data and on-site performance to improve...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Greg IRACE Anne WHITAKER Sanofi Shifts U.S. Leadership Sanofi has named Greg Irace senior VP, global services. Mr. Irace leads the global information systems function and is responsible for shared support functions across all Sanofi businesses in North America. He also plays a...
By PharmaVoice Team • Sept. 27, 2011
Previous
